These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33740205)

  • 41. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
    Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repeat lumpectomy for patients with ipsilateral breast tumor recurrence after breast-conserving surgery. Preliminary results.
    Komoike Y; Motomura K; Inaji H; Kasugai T; Koyama H
    Oncology; 2003; 64(1):1-6. PubMed ID: 12457024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
    Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
    Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy.
    Viswambharan JK; Kadambari D; Iyengar KR; Srinivasan K
    Indian J Cancer; 2005; 42(1):30-4. PubMed ID: 15805689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Attitudes of Canadian radiation oncologists towards post-lumpectomy radiotherapy for elderly women with stage I hormone-responsive breast cancer.
    Warner E; Chow E; Fairchild A; Franssen E; Paszat L; Szumacher E
    Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):97-106. PubMed ID: 19883996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Ishitobi M; Matsuda N; Tazo M; Nakayama S; Tokui R; Ogawa T; Yoshida A; Kojima Y; Kuwayama T; Nakayama T; Yamauchi H; Nakamura S; Tsugawa K; Hayashi N
    Ann Surg Oncol; 2021 May; 28(5):2545-2552. PubMed ID: 33021710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant chemotherapy in the treatment of breast cancer.
    Redden MH; Fuhrman GM
    Surg Clin North Am; 2013 Apr; 93(2):493-9. PubMed ID: 23464698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Axillary management for patients with breast cancer after neoadjuvant chemotherapy: Results of a survey among Brazilian breast surgeons.
    Frasson AL; Resende HM; Lichtenfels M; Barbosa F; de Souza ABA; Miranda I; Falcone AB
    J Surg Oncol; 2020 Nov; 122(6):1247-1251. PubMed ID: 33045117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surgical management of early stage invasive breast cancer: a practice guideline.
    McCready D; Holloway C; Shelley W; Down N; Robinson P; Sinclair S; Mirsky D; ;
    Can J Surg; 2005 Jun; 48(3):185-94. PubMed ID: 16013621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breast-conservation Therapy After Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer-specific Mortality.
    Arlow RL; Paddock LE; Niu X; Kirstein L; Haffty BG; Goyal S; Kearney T; Toppmeyer D; Stroup AM; Khan AJ
    Am J Clin Oncol; 2018 Dec; 41(12):1246-1251. PubMed ID: 29782362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
    Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
    Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 57. Physician sex and other factors associated with type of breast cancer surgery in older women.
    Cyran EM; Crane LA; Palmer L
    Arch Surg; 2001 Feb; 136(2):185-91. PubMed ID: 11177139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.